Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA.

Peroxiredoxin 5 (PRDX5) is a mammalian thioredoxin peroxidase ubiquitously expressed in tissues. Its role as antioxidant enzyme has been previously supported in different pathological situations. In this study, we determined the complete human PRDX5 genomic organization and isolated the 5'-flanking region of the gene. Human PRDX5 gene is composed of six exons and five introns similarly to other chordate PRDX5 genes. Several single nucleotide polymorphisms were identified. Six out of them have amino acid substitutions in protein-coding region. Analysis of the 5'-flanking region of human PRDX5 revealed the presence of a TATA-less promoter containing a canonical CpG island and several putative response elements for transcription factors. To analyze the regulatory mechanisms controlling human PRDX5 expression, we characterized the 5'-flanking region by cloning various segments of this region in front of a luciferase reporter sequence. Transfection in HepG2 cells indicate that the 5'-flanking region contains regulatory elements for constitutive expression of human PRDX5. Multiple transcription start sites were also identified by 5'-RACE-PCR in human liver. Moreover, although no corresponding proteins were reported, we present new alternative splicing variants encoded specifically by human PRDX5 gene. The characterization of human PRDX5 gene revealed the complexity of its regulation and a high variability of sequences that might be associated with pathological situations.

SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties.

SL65.0155 [5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phenyl ethyl)-4-piperidinyl]-1,3,4-oxadiazol-2(3H)-one monohydrochloride] is a novel benzodioxanoxadiazolone compound with high affinity for human 5-hydroxytryptamine (5-HT)(4) receptors (K(i) of 0.6 nM) and good selectivity (greater than 100-fold for all other receptors tested). In cells expressing the 5-HT(4(b)) and 5-HT(4(e)) splice variants, SL65.0155 acted as a partial agonist, stimulating cAMP production with a maximal effect of 40 to 50% of serotonin. However, in the rat esophagus preparation, SL65.0155 acted as a 5-HT(4) antagonist with a pK(b) of 8.81. In addition, SL65.0155 potently improved performance in several tests of learning and memory. In the object recognition task, it improved retention at 24 h when administered i.p. or p.o. (0.001-0.1 mg/kg). This effect was antagonized by the 5-HT(4) antagonist SDZ 205,557, itself without effect, demonstrating that the promnesic effects of SL65.0155 are mediated by 5-HT(4) agonism. SL65.0155 also reversed the cognitive deficits of aged rats in the linear maze task and the scopolamine-induced deficit of mice in the water maze task. Furthermore, the combined administration of an inactive dose of SL65.0155 with the cholinesterase inhibitor rivastigmine resulted in a significant promnesic effect, suggesting a synergistic interaction. SL65.0155 was devoid of unwanted cardiovascular, gastrointestinal, or central nervous system effects with doses up to more than 100-fold higher than those active in the cognitive tests. These results characterize SL65.0155 as a novel promnesic agent acting via 5-HT(4) receptors, with an excellent preclinical profile. Its broad range of activity in cognitive tests and synergism with cholinesterase inhibitors suggest that SL65.0155 represents a promising new agent for the treatment of dementia.

Homotopic septal grafts combined with a hydrogel bridge promote functional recovery in rats with fimbria-fornix lesions: A unit recording study.

Fimbria-fornix lesions abolish the hippocampal electrophysiological activity time-locked to the theta rhythm and alter some functional characteristics of place cells. The present experiment investigated whether homotopic grafts of fetal septal cells can alleviate some of these alter-ations when combined with a polymeric hydrogel bridging a fimbria-fornix lesion-cavity. Eleven months after grafting surgery, unit recordings were obtained from hippocampal neurons of seven rats [two sham-operated (S), two lesion-only (L) and three grafted (G)] while they explored a radial maze. The lesions induced dramatic loss of hippocampal acetylcholinesterase(AChE)-positive reaction products. Surviving grafts were found in the three grafted rats and several AChE-positive processes could be observed in the polymeric hydrogel, as well as in the most dorsal portion of the hippocampal parenchyma. Of 168 recorded units, 132 were hippocampal interneurons (i.e., fired rapidly everywhere in the maze), and 36 were pyramidal place cells (i.e., fired only when the rat was in a specific location in the maze, the place field). The overall firing characteristics of either cell type were similar in S, L and G rats. However, while none of the interneurons recorded from L rats was found to fire rhythmically, a significant proportion of interneurons recorded from S and G rats had an activity pattern time-locked to the theta rhythm [S: 16/19 (84 %); G : 22/70 (31 %)]. In addition, the increase in firing activity observed in interneurons recorded from S rats when they were moving was disrupted in cells from L rats, but partially restored in cells from G rats. Concerning place cells, most (93 %) place fields in S rats were stable relative to extra-maze cues when the radial maze was rotated, while they followed the maze rotation in both L and G rats. Because of the low number of rats used, the present results should be considered with caution. Nevertheless, they indicate graft-induced recovery of some properties of hippocampal function following fimbria-fornix damage, and suggest that homotopic transplants of projection neurons may foster some func-tional recovery when provided with a biomaterial allowing the host or grafted neurons to cross the lesion cavity.